Previous 10 | Next 10 |
Savara ( NASDAQ: SVRA ) Badrul Chowdhury resigned as chief medical officer, effective Sept. 9. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future," ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. “We appreciate Dr. Chowdhury&...
Savara ( NASDAQ: SVRA ) said on Aug. 25 that the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to the company's inhaled therapy molgramostim to treat autoimmune pulmonary alveolar protein...
PIM Designation Recognizes Molgramostim as a Promising Candidate for the UK Early Access to Medicines Scheme (EAMS) – A Program that Aims to Give Patients with Life Threatening or Seriously Debilitating Conditions with Unmet Medical Need Access to Medicines That Do Not Yet Have...
Savara press release ( NASDAQ: SVRA ): Q2 GAAP EPS of -$0.06 in-line. “Despite ongoing factors such as geographical COVID surges, geopolitical issues and supply chain constraints, IMPALA-2, the pivotal Phase 3 trial of our novel inhaled biologic, is currently on-tra...
Pivotal Phase 3 IMPALA-2 Trial of Novel Inhaled Biologic, Molgramostim Nebulizer Solution (Molgramostim), in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Remains On-Track IMPALA-2 Top Line Data Expected at the End of 2Q 2024 Company Ends Quarter with ~$14...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Ba...
Savara (NASDAQ:SVRA) said its inhaled biologic molgramostim was granted an innovation passport designation by the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) to treat Pulmonary Alveolar Proteinosis (aPAP), a rare autoimmune lung disease. Innovation Passpor...
Innovation Passport Awarded to Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a Rare Lung Disease The Innovation Passport, a UK Designation for Innovative Medicines, is the Entry Point to the Innovative Licensing and Access Pathway (ILAP), ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentatio...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...